Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Business of Medicine

Articles with lock require a GLG News subscription
Posted May 20, 2008
Big Pharma Losing Control
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Member Program Contributor
For too long big pharma has dictated which drugs will come to market and what they will cost.  The entire American healthcare system is literally collapsing because of two costs:  medications and bureacracy.  Expect more payers to look for ways to bring down costs in the fu...
Posted May 19, 2008
Phase 3 without Phases 1 and 2
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Member Program Contributor
This article warns against "taking testing out of the hands of companies" and warns against the idea that a drug is receiving a Phase 3 trial without early phase testing.  The CATT trial certainly marks a huge change in drug development but what the pharma industry is not appreciating...
Posted May 19, 2008
The Required Success Factorsfor China to Muscle into Genetic Industry
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Member Program Contributor
GMP Compliance QC/QA/Validation Facility Engineering and Construction Capabilities
Brian Abbott Posted May 19, 2008
National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: Brian Abbott, Medical Director of Hematology Big Sky Oncology
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
Brian Abbott Posted May 19, 2008
Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com
Author: Brian Abbott, Medical Director of Hematology Big Sky Oncology
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
Posted May 19, 2008
Income Streams and Salmon
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Member Program Contributor
IMS, a publically traded healthcare consutancy has concerns about the CATT study, funded by the National Eye Institute. Given their award winning reputation, one might worry that IMS has uncovered a real problem. Think again. 1. Among IMS' main customers are those who seek pharmaceutical intelligence...
Posted May 19, 2008
Change is coming get on board or lose
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Member Program Contributor
Payers seek to lessen their exposure to rising costs. Pharma needs to create a Value Statement in their TPP. Standard of care will dictate utilization and market share.
Posted May 19, 2008
Giving Credit Where Credit's Due for Hospital Tech Spending
Analysis of: S&P to Watch Hospital Tech Spending | www.modernhealthcare.com
Author: GLG Member Program Contributor
The Standard and Poor's Credit Rating Agency has just made a compelling case why nonprofit hospitals need to spend more on advanced technology (both to improve patient care directly through better diagnosis and treatment and through information technology to enhance safety).  The credit rating...
Posted May 16, 2008
Bad show for Big Pharma
Analysis of: US trade agency wants to end deals delaying generics | www.reuters.com
Author: GLG Member Program Contributor
If this indeed occurs it should be a great help to the cost of healthcare. Many drugs which remain on patent are clearly more expensive than generics. As the public becomes aware of this, the trust in Big Pharma will erode further.
Posted May 15, 2008
Production techniques cause unsafe heparin to be spread through the world resulting in mortality
Analysis of: U.S. Identifies Tainted Heparin in 11 Countries | www.nytimes.com
Author: GLG Member Program Contributor
The issues are several: A wave of disease infected and killed many Chinese pigs (whose intestines are raw source material for heparin) and this drove up prices while decreasing supply. Heparin is a low cost, generic drug requiring an extremely tight supply chain to keep costs down.  ...
Previous Page : 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next211 to 220 of 648

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617